FDA OKs first generic for Gleevec leukemia pill

FDA OKs first generic for Gleevec leukemia pill

U.S. regulators have approved a generic version of one of the first very effective — & expensive — cancer drugs, Gleevec (GLEE'-vek).

The Food & Drug Administration granted a subsidiary of Indian drugmaker Sun Pharmaceutical Industries Ltd. approval to sell generic Gleevec pills, known chemically as imatinib mesylate, in 100-milligram & 400-milligram doses for chronic myeloid leukemia.

Sun Pharmaceutical, one of the world's biggest makers of generic medicines, says it will commence selling the pills in the U.S. on Feb. 1, 2016.

p>Gleevec, which was developed & is sold by Swiss drugmaker Novartis AG, was approved in 2003.

According to Sun, Gleevec has approximately $2.5 billion in annual sales in the U.S. It currently has a U.S. list price of approximately $10,000 per month for the more-common 400-milligram daily dosage.

Source: “Associated Press”